Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy

Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy

Objectives: The impact of very low-level viremia (VLLV) and low-level viremia (LLV) are rarely investigated among people living with HIV (PLWH) receiving dolutegravir- vs protease inhibitor (PI)-based antiretroviral therapy (ART). Methods: Virally suppressed PLWH receiving long-term PI-containing AR...

Full description

Bibliographic Details
Main Authors:	Guan-Jhou Chen, Hsin-Yun Sun, Sui-Yuan Chang, Aristine Cheng, Yu-Shan Huang, Sung-Hsi Huang, Yi-Chia Huang, Yi-Ching Su, Wen-Chun Liu, Chien-Ching Hung
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	International Journal of Infectious Diseases
Subjects:	Integrase strand transfer inhibitor Nucleoside reverse transcriptase inhibitor Virological failure Resistance-associated mutation Genetic barrier
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971221001314

Similar Items

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
by: Daniel M. Himmel, et al.
Published: (2020-06-01)

Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
by: Fernandez C, et al.
Published: (2019-07-01)

Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa
by: Adetayo Emmanuel Obasa, et al.
Published: (2020-03-01)

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
by: Nicola Gianotti, et al.
Published: (2017-11-01)

Mutations in the Reverse Transcriptase and Protease Genes of Human Immunodeficiency Virus-1 from Antiretroviral Naïve and Treated Pediatric Patients
by: Dinesh Bure, et al.
Published: (2015-02-01)

Antiretroviral Drug Interactions: Overview of Interactions Involving New and Investigational Agents and the Role of Therapeutic Drug Monitoring for Management
by: R. Chris Rathbun, et al.
Published: (2011-10-01)

How can we achieve universal access to low-cost treatment for HIV?
by: Andrew M. Hill, et al.
Published: (2016-10-01)

Future implications: Compliance and failure with antiretroviral treatment
by: Patel Atul, et al.
Published: (2006-01-01)

Current Treatment of HIV Infection
by: Behice KURTARAN
Published: (2015-12-01)

High Performance Liquid Chromatographic Assay for the Determination of Protease Inhibitors (PIs) and Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in Human Plasma
by: Kantima Sangsiriwut, et al.
Published: (2020-07-01)

Antiretroviral treatment and time since HIV-1 diagnosis are associated with large artery stiffness in sub-Saharan African HIV-1 patients
by: Titus F. Msoka, et al.
Published: (2016-10-01)

Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa
by: Adetayo Emmanuel Obasa, et al.
Published: (2021-02-01)

HIVprotI: an integrated web based platform for prediction and design of HIV proteins inhibitors
by: Abid Qureshi, et al.
Published: (2018-03-01)

Dolutegravir-based anti-retroviral therapy is effective and safe in HIV–infected paediatric patients
by: Eugenia Bruzzese, et al.
Published: (2018-03-01)

Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan
by: Yu-Tzu Tseng, et al.
Published: (2014-12-01)

Liver Fibrosis during Antiretroviral Treatment in HIV-Infected Individuals. Truth or Tale?
by: Athanasios-Dimitrios Bakasis, et al.
Published: (2021-05-01)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
by: Valeria Famiglini, et al.
Published: (2016-02-01)

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
by: Pablo Ferrer, et al.
Published: (2020-09-01)

Antiretroviral therapy-induced Leber’s hereditary optic neuropathy
by: Anand Moodley, et al.
Published: (2014-05-01)

Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen
by: Jean Michel Petit, et al.
Published: (2003-09-01)

Distal sensory polyneuropathy in human immunodeficiency virus patients and nucleoside analogue antiretroviral agents
by: Jose Jimmy, et al.
Published: (2007-01-01)

Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase
by: Stefan G. Sarafianos, et al.
Published: (2010-02-01)

Elucidation on the Physicochemical Properties of Potential and Clinically Approved Antiviral Drugs: A Search for Effective Therapies against SARS-CoV-2 Infection
by: Derick Erl P. Sumalapao
Published: (2020-05-01)

Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data
by: Rock AE, et al.
Published: (2020-06-01)

The role of rilpivirine in Southern Africa
by: Michelle A. Moorhouse, et al.
Published: (2019-05-01)

Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance
by: Nicole Bertoletti, et al.
Published: (2020-10-01)

Drug Resistance in Non-B Subtype HIV-1: Impact of HIV-1 Reverse Transcriptase Inhibitors
by: Kamalendra Singh, et al.
Published: (2014-09-01)

Développement d'inhibiteurs de la dimérisation du complexe de la Reverse Transcription du VIH-1
by: Moustapha Abba Moussa, Daouda
Published: (2013)

Previous antiretroviral drug use compromises standard first-line HIV therapy and is mediated through drug-resistance
by: Seth C. Inzaule, et al.
Published: (2018-10-01)

First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
by: Joseph Fokam, et al.
Published: (2020-08-01)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
by: Eva Wolf, et al.
Published: (2021-09-01)

Can Antiretroviral Drugs Be Used to Treat Porcine Endogenous Retrovirus (PERV) Infection after Xenotransplantation?
by: Joachim Denner
Published: (2017-08-01)

Docking study on anti-HIV-1 activity of secondary metabolites from Zingiberaceae plants
by: Muhammad Sulaiman Zubair, et al.
Published: (2020-01-01)

Will Drug Resistance against Dolutegravir in Initial Therapy Ever Occur?
by: Mark eWainberg, et al.
Published: (2015-04-01)

2'-Deoxythymidine Adducts from the Anti-HIV Drug Nevirapine
by: M. Matilde Marques, et al.
Published: (2013-04-01)

Antiretroviral Therapies for Human Immunodeficiency Virus and Liver Disease: Challenges and opportunities
by: Julio C. Abarca, et al.
Published: (2020-03-01)

Multiple choices for HIV therapy with integrase strand transfer inhibitors
by: Raffi Francois, et al.
Published: (2012-12-01)

Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors
by: Peter V. Coveney, et al.
Published: (2012-07-01)

Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date
by: Hill L, et al.
Published: (2018-10-01)

The role of the protease cleavage sites in viral fitness and drug resistance in HIV-1 subtype C.
by: Giandhari, Jennifer.
Published: (2013)